ANI Pharma (ANIP) Tops Q3 EPS by 17c

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.80, $0.17 better than the analyst estimate of $0.63. Revenue for the quarter came in at $20 million versus the consensus estimate of $21.37 million.

ANI Pharma sees Q4 2015 EPS of $0.60-$0.76, versus the consensus of $0.70. ANI Pharma sees Q4 2015 revenue of $17.2-20.0 million, versus the consensus of $22.7 million.

ANI Pharma sees FY2015 EPS of $2.83-$2.96, versus the consensus of $2.44. ANI Pharma sees FY2015 revenue of $75.5-78.3 million, versus the consensus of $82.4 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Halozyme prices $1.3B convertible notes offering due 2033
• Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance